IMMUNOLOGY*today*

Subject Index

Author Index

Books reviewed

1993

Vol 14
Issues 1–12

ISSN 0167 5699

Immunology Today

Elsevier Trends Journals
68 Hills Road
Cambridge
UK, CB2 1LA
Tel +44 (0) 223 315961
Fax +44 (0) 223 464430

Advisory Editorial Board
F. H, Bach, *Minneapolis, USA*
J. F. Bach, *Paris, France*
M. D. Cooper, *Birmingham, USA*
C. A. Janeway Jr, *New Haven, USA*
T. Kishimoto, *Osaka, Japan*
P. Lachmann, *Cambridge, UK*
D. Mathis, *Strasbourg, France*
F. Melchers, *Basel, Switzerland*
T. Mosmann, *Edmonton, Canada*
G. J. V. Nossal, *Melbourne, Australia*
J. H. L. Playfair, *London, UK*
R. H. Schwartz, *Bethesda, USA*
E. Simpson, *Harrow, UK*
R. Zinkernagel, *Zürich, Switzerland*

Editor
Robert Brines

Assistant Editor
Louise Walsh

Editorial Secretaries
Lucy Greenberry, Helen Steele

Copyright © 1994 Elsevier Science Ltd

All rights reserved. No part of this publication may be translated, reproduced, stored in an electronic retrieval system, published or transmitted, in any form or by any means, such as but not limited to, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the copyright owner and the publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge UK CB2 1LA.

Author Index

(BR): Book review
(L) : Letter to the Editor

A
Acha-Orbea, H., *see* Heber-Katz, E. 380
Adams, D.H., *see* Tanaka, Y. 111
Ádány, R., Janus-faced tumor associated macrophages (L) 142
Adorini, L., Guéry, J-C., Rodriguez-Tarduchy, G. and Trembleau, S., Selective immunosuppression 285
Akbar, A.N., Salmon, M., Savill, J. and Janossy, G., A possible role for *bcl-2* in regulating T-cell memory – a 'balancing act' between cell death and survival 526
Allen, P.M., *see* Evavold, B.D. 602
André, P., *see* Wade, W.F. 539
Arlaud, G.J., *see* Dierich, M.P. 435
Armitage, R.J., *see* Callard, R.E. 559
Arnaiz-Villena, A., MHC research: fast forward 3
Arnold, B., Schönrich, G. and Hämmerling, G.J., Multiple levels of peripheral tolerance 12
Arnold, L.W., *see* Haughton, G. 84, 88
Aste, M., *see* Trinchieri, G. 237
Atlan, H., Gersten, M.J., Salk, P.L. and Salk, J., Can AIDS be prevented by T-cell vaccination? 200
Aubry, J-P., *see* Bonnefoy, J-Y. 1
Audibert, F.M. and Lise, L.D., Adjuvants: current status, clinical perspectives and future prospects 281
Axford, J.S., Second Jenner International Glycoimmunology Meeting 104

B
Bach, J-F., Fracchia, G.N. and Chatenoud, L., Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy 421
Bach, J-F., Immunosuppressive therapy of autoimmune diseases 322
Balkwell, F.R., *see* Burke, F. 165
Balkwill, F.R., Cytokines in health and disease 149
Bauer, S., *see* Melchers, F. 60
Beales, P.E., *see* Pozzilli, P. 193
Bean, A.G.D., *see* Boyd, R.L. 445
Beaven, M.A. and Metzger, H., Signal transduction by Fc receptors: the FcεRI case 222
Beaven, M.A., *see* Santini, F. 369
Bellone, M., *see* Protti, M-P. 363
Berek, C. and Ziegner, M., The maturation of the immune response 400
Bertoglio, J., *see* Chavrier, P. 440
Betz, A.G., Neuberger, M.S. and Milstein, C., Discriminating intrinsic and antigen-selected mutational hotspots in immunoglobulin *V* genes 405
Blackman, M.A., *see* Woodland, D.L. 208
Bona, C., *see* Rose, N.R. 426
Bonnefoy, J-Y., Pochon, S., Aubry, J-P., Graber, P., Gauchat, J-F., Jansen, K. and Flores-Romo, L., A new pair of surface molecules involved in human IgE regulation 1
Bootsma, H.J., *see* Verduin, C.M. 44
Borrebaeck, C.A.K., Malmborg, A-C and Ohlin, M., Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? 477
Bos, J.D. and Kapsenberg, M.L., Skin immune system: progress in cutaneous biology 75
Boyd, R.L., *see* Ritter, M.A. 462
Boyd, R.L., Tucek, C.L., Godfrey, D.I., Izon, D.J., Wilson, T.J., Davidson, N.J., Bean, A.G.D., Ladyman, H.M., Ritter, M.A. and Hugo, P., Full colour poster: The thymic microenvironment 445
Bradley, L.M., Croft, M. and Swain, S.L., T-cell memory: new perspectives 197
Brandtzaeg, P., *see* Hanson, L.Å. 416
Brines, R., *see* Gallagher, R.B. 241
Broder, S., *see* Yarchoan, R. 303
Browning, M. and Chapel, H.M., Manual of Clinical Laboratory Immunology, 4th Edition (BR) 145
Burke, F., Naylor, M.S., Davies, B. and Balkwell, F.R., Centrefold: The cytokine wall chart 165

C
Cabrera, T., *see* Garrido, F. 491
Callard, R.E., Armitage, R.J., Fanslow, W.C. and Spriggs, M.K., CD40 ligand and its role in X-linked hyper-IgM syndrome 559
Cambier, J., *see* Wade, W.F. 539
Cambouropoulos, P.J. and Nash, A.A., Herpes Simplex Virus – Pathogenesis, Immunobiology and Control (BR) 144
Campbell, R.D. and Trowsdale, J., Centrefold: Map of the human MHC 349
Capel, P.J.A., *see* van de Winkel, J.G.J. 215
Casanova, J-L. and Maryanski, J.L., Antigen-selected T-cell receptor diversity and self-nonself homology 391
Casanova, J.M., A Very Decided Preference – Life With Peter Medawar (BR) 46
Chan, E., *see* MacLennan, I. 29
Chapel, H.M., *see* Browing, M. 145
Chatenoud, L., *see* Bach, J-F. 421
Chavrier, P., Gorvel, J-P. and Bertoglio, J., An immunologist's look at the rho and rab GTP-binding proteins 440
Chehimi, J., *see* Trinchieri, G. 237
Chen, L., Linsley, P.S. and Hellström, K.E., Costimulation of T cells for tumor immunity 483
Chien, Y-h. and Davis, M.M., How αβ T-cell receptors 'see' peptide/MHC complexes 597
Clarke, S.H., *see* Haughton, G. 84
Clarke, S.H., *see* Haughton, G. 88
Clerici, M. and Shearer, G.M., A $T_H1 \rightarrow T_H2$ switch is a critical step in the etiology of HIV infection 107
Clevers, H.C., Oosterwegel, M.A. and Georgopoulos, A., Transcription factors in early T-cell development 591
Cobbold, S., *see* Waldmann, H. 247
Coffman, R.L., *see* Powrie, F. 270
Cohen, J.J., Apoptosis 126
Cohn, M., *see* Langman, R.E. 235
Colaco, C.A.L.S., Secretory pathway components: targets for autoimmunity (L) 44
Concha, A., *see* Garrido, F. 491
Conti-Tronconi, B.M., *see* Protti, M-P. 363
Cooper, E.L., Reply to Smith and Davidson (L) 92
Cooper, K.D., *see* Wong, R.L. 69
Coulson, A.F.W., *see* Jones, D.B. 115
Coutinho, A., Lymphocyte survival and V-region repertoire selection 38
Coutinho, A., *see* Kazatchkine, M. 513
Crispe, N., Flow Cytometry: First Principles (BR) 418
Croft, M., *see* Bradley, L.M. 197
Cunningham, E.T. and De Souza, E.B., Interleukin 1 receptors in the brain and endocrine tissues 171
Cunningham, E.T., Interleukin-1 in the brain (BR) 471
Cushley, W., Mechanisms of Lymphocyte Activation and Immune Regulation III: Developmental Biology of Lymphocytes (BR) 471

D
D'Andrea, A., *see* Trinchieri, G. 237
Davidson, E.H., *see* Smith, L.C. 93
Davidson, N.J., *see* Boyd, R.L. 445
Davies, A.J., The Tale of T-cells 137
Davies, B., *see* Burke, F. 165
Davis, M.M., *see* Chien, Y-h. 597
Davoust, J., *see* Wade, W.F. 539
Dawson, J.R., The Natural Killer Cell (BR) 96
Dayan, C.M., *see* Lehmann, P.V. 203
De Simone, C., Famularo, G., Tzantzoglou, S. and Paoletti, F.,

Soluble CD14 antigen in patients with AIDS (L) 515
De Souza, E.B., *see* Cunningham, E.T. 171
De Strooper, B., Van Leuven, F., α2-macroglobulin and subacute-phase reponses in Alzheimers disease (L) 143
Delhase, M., *see* Hooghe, R. 212
Demetris, A.J., *see* Starzl, T.E. 326
Dierich, M.P., Ebenbichler, C.F., Marschang, P., Füst, G., Thielends, N.M. and Arlaud, G.J., HIV and human complement: mechanisms of interaction and biological implication 435
Dinarello, C.A., Modalities for reducing interleukin 1 activity in disease 260
Duff, G.W., *see* Jones, D.B. 115

E
Ebenbichler, C.F., *see* Dierich, M.P. 435
Erlanger, B.F., Why cyclosporin is an effective drug (L) 369
Evavold, B.D., Sloan-Lancaster, J. and Allen, P.M., Tickling the TCR: Selective T-cell functions stimulated by altered peptide ligands 602

F
Fadok, V., *see* Savill, J. 131
Famularo, G., *see* De Simone, C. 515
Fanslow, W.C., *see* Callard, R.E. 559
Flores-Romo, L., *see* Bonnefoy, J-Y. 1
Forsthuber, T., *see* Lehmann, P.V. 203
Fox, C., Cytotoxic T Cells in HIV and Other Retroviral Infections (BR) 238
Fracchia, G.N., *see* Bach, J-F. 421
Fraser, J.D., Straus, D. and Weiss, A., Signal transduction events leading to T-cell lymphokine gene expression 357
Freitas, A.A. and Rocha, B.B., Lymphocyte life-spans: homeostasis, selection and competition 25
Fuchs, E. and Matzinger, P., Do B cells drive the diversification of immune responses?: Comment 153
Fuchs, E., Two signal models of lymphocyte activation?: Comment (L) 236
Füst, G., *see* Dierich, M.P. 435

G
Galili, U., Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans 480
Gallagher, R.B., Brines, R. and Girdlestone, D., Why immunopharmacology? 241
Gammon, G., *see* Lehmann, P.V. 203
Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F. and Stern, P.L., Natural history of HLA expression during tumor development 491
Gauchat, J-F., *see* Bonnefoy, J-Y. 1
Gearing, A.J.H. and Newman, W., Circulating adhesion molecules in disease 506
Gearing, A.J.H., Human Cytokines: Handbook for Basic and Clinical Research (BR) 47
Geenen, V. and Kroemer, G., Multiple ways to cellular immune tolerance 573
Georgopoulos, A., *see* Clevers, H.C. 591
Georgopoulos, C. and McFarland, H., Heat shock proteins in Multiple Sclerosis and other autoimmune diseases 373
Gersten, M.J., *see* Atlan, H. 200
Gill, R.G. and Haskins, K., Molecular mechanisms underlying diabetes and other autoimmune diseases 49
Girdlestone, D., *see* Gallagher, R.B. 241
Gladstone, P., AIDS progression; protection by T_H1 lymphokines in different HLA-DR genotypes (L) 417
Glew, S., *see* Garrido, F. 491
Godard, P., Allergic Diseases: Diagnosis and Management (BR) 472
Godrey, D.I. and Zlotnik, A., Control points in early T-cell development 547
Godfrey, D., *see* Boyd, R.L. 445
Gold, D.P., *see* Wilson, D.B. 376
Goldenberg, D.M. and Schlom, J., The coming of age of cancer radioimmunoconjugates 5
Gorvel, J-P., *see* Chavrier, P. 440
Graber, P., *see* Bonnefoy, J-Y. 1
Graham, G., Cell Biology: Labfax (BR) 371
Green, D.R. and Webb, D.R., Saying the 'S' word in public 523
Groettrup, M. and von Boehmer, H., A role for a pre-T-cell receptor in T-cell development 610
Guéry, J-C., *see* Adorini, L. 285
Guilbert, L., *see* Wegmann, T.G. 353
Guy-Grand, D., *see* Rocha, B. 141

H
Haasner, D., *see* Melchers, F. 60
Hadden, J.W. and Kishimoto, T., Introduction to immunopharmacology 242
Hadden, J.W., Immunostimulants 275
Hamilton, J.A., Colony stimulating factors, cytokines and monocyte-macrophages – some controversies 18
Hämmerling, G.J., *see* Arnold, B. 12
Hannet, I., Reply to Racadot (L) 190
Hanson, L.Å. and Brandtzaeg, P., The discovery of secretory IgA and the mucosal immune system (L) 416
Hardy, R., The nature of B-cell subpopulations: comment 90
Harris, W.J., *see* Winter, G. 243
Haskins, K., *see* Gill, R.G. 49
Haslett, C., *see* Savill, J. 131
Haughn, L., *see* Julius, M. 177
Haughton, G., Arnold, L.W., Whitmore, A.C. and Clarke, S.H., B-1 cells are made, not born 84
Haughton, G., Arnold, L.W., Whitmore, A.C. and Clarke, S.H., The nature of B-cell subpopulations: comment 88
Hawrylowicz, C., New Advances on Cytokines (BR) 470
Hay, F.C., Jones, M.G., Soltys, A. and Horsfall, A., British Society for Immunology – epitope mapping workshop 102
Hayday, A., *see* Palmer, D.B. 460
Heber-Katz, E. and Acha-Orbea, H., reply to Wilson, Steinman and Gold 380
Helbert, M.R., L'Age-Stehr, J. and Mitchison, N.A., Antigen presentation, loss of immunological memory and AIDS 340
Hellström, K.E., *see* Chen, L. 483
Henson, P., *see* Savill, J. 131
Herrlich, P., Zöller, M., Pals, S.T. and Ponta, H., CD44 splice variants: metastases meet lymphocytes 395
Herzenberg, L.A. and Kantor, A.B., B-cell lineages exist in the mouse 79
Herzenberg, L.A. and Kantor, A.B., The nature of B-cell subpopulations: comment 87
Heyman, B., A third way to induce crosslinking of membrane immunoglobulin and CR2? (L) 515
Hinshelwood, S., *see* Kinnon, C. 554
Hirose, S., *see* Kimoto, M. 569
Hol, C., *see* Verduin, C.M. 44
Hooghe, R., Delhase, M., Vergani, P., Malur, A. and Hooghe-Peters, E.L., Growth hormone and prolactin are paracrine growth and differentiation factors in the haemopoietic system 212
Hooghe-Peters, E.L., *see* Hooghe, R. 212
Horsfall, A., *see* Hay, F.C. 102
Horton, R.M., *see* Protti, M-P. 363
Hsu, P-L., *see* Sell, S. 576
Hugo, P., *see* Boyd, R.L. 445

I
Ihrcke, N.S., Wrenshall, L.E., Lindman, B.J. and Platt, J.L., Role of heparan sulphate in immune system-blood vessel interactions 500
Ikawa, Y., *see* Sugimoto, M. 190
Imhof, B.A., *see* Mackay, C.R. 99
Isenberg, D., *see* Zouali, M. 473
Izon, D., *see* Boyd, R.L. 445

J
Jameson, B., *see* Melchers, F. 60
Janeway, C.A., Jr, *see* Mamula, M.J. 151
Janossy, G., *see* Akbar, A.N. 526
Jansen, K., *see* Bonnefoy, J-F. 1
Jefferis, R., What is an idiotype? 119
Jones, D.B., Coulson, A.F.W. and Duff, G.W., Sequence homologies

between HSP60 and autoantigens 115
Jones, M.G., *see* Hay, F.C. 102
Julius, M., Maroun, C.R. and Haughn, L., Distinct roles for CD4 and CD8 as co-receptors in antigen receptor signalling 177
Julius, M., *see* Poussier, P. 140

K
Kabelitz, D., Pohl, T. and Pechhold, K., Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes 338
Kaetzel, C.S., *see* Mazanec, M.B. 430
Kaiserlian, D. and Vidal, K., Antigen presentation by intestinal epithelial cells (L) 144
Kalsi, J., *see* Zouali, M. 473
Kantor, A.B., *see* Herzenberg, L.A. 79
Kantor, A.B., *see* Herzenberg, L.A. 87
Kapsenberg, M.L., *see* Bos, J.D. 75
Karasuyama, H., *see* Melchers, F. 60
Karp, R.D., The echinoid immune system revisited: reply to Smith and Davidson (L) 91
Kaye, P.M., Infectious Diseases of Humans: Dynamics and Control (BR) 616
Kazatchkine, M.D., and Coutinho, A., Are lymphocytes concerned with our definition of idiotypes? 513
Kazatchkine, M.D., Clinical Applications of Intravenous Immunoglobulin Therapy (BR) 48
Kennedy, J.R., Destructive networks in AIDS (L) 615
Kepler, T.B. and Perelson, A.S., Cyclic re-entry of germinal center B cells and the efficiency of affinity maturation 412
Kimoto, M., Nishimura, H., Hirose, S. and Shirai, T., MHC heterozygosity and autoimmunity (L) 569
Kingsley, G. and Sieper, J., Current perspectives in reactive arthritis 387
Kinnon, C., Hinshelwood, S., Levinsky, R.J. and Lovering, R.C., Immunodeficiency: X-linked agammaglobulinemia – gene cloning and future prospects 554
Kioussis, D., Molecular Mechanisms of Immunological Self-Recognition (BR) 419
Kishimoto, T., *see* Hadden, J.W. 242
Kroemer, G., *see* Geenen, V. 573
Krueger, J.M., Neuroimmunology of Fever (BR) 571
Kubin, M., *see* Trinchieri, G. 237
Kudo, A., *see* Melchers, F. 60

L
L'Age-Stehr, J., *see* Helbert, M.R. 340
Ladyman, H.M., *see* Boyd, R.L. 445
Lambris, J.D., *see* Tsoukas, C.D. 56
Lamm, M.E., *see* Mazanec, M.B. 430
Langman, R.E., and Cohn, M., Two signal models of lymphocyte activation? (L) 235
Lankester, A.C., *see* van Noessel, C.J.M. 8
Lannes-Vieira, J., *see* Savino, W. 158
Lehmann, P.V., Sercarz, E.E., Forsthuber, T., Dayan, C.M. and Gammon, G., Determinant spreading and the dynamics of the autoimmune T-cell repertoire 203
Lehr, H-A., *see* Menger, M.D. 519
Levinsky, R.J., *see* Kinnon, C. 554
Lin, H., *see* Wegmann, T.G. 353
Lindman, B.J., *see* Ihrcke, N.S. 500
Linsley, P.S., *see* Chen, L. 483
Lise, L.D., *see* Audibert, F.M. 281
Liu, F-T., S-type mammalian lectins in allergic inflammation 486
Liu, J., FK506 and cyclosporin, molecular probes for studying intracellular signal transduction 290
Lovering, R.C., *see* Kinnon, C. 554
Lunney, J.K., Characterization of swine leukocyte differentiation antigens 147
Lynch, R.G., *see* Sandor, M. 227

M
Mackay, C.R. and Imhof, B.A., Cell adhesion in the immune system 99
MacLennan, I. and Chan, E., The dynamic relationship between B-cell populations in adults 29
Malmborg, A-C, *see* Borrebaeck, C.A.K. 477
Malur, A., *see* Hooghe, R. 212
Mamula, M.J. and Janeway, C.A., Jr., Do B cells drive the diversification of immune responses? 151
Manfredi, A.A., *see* Protti, M-P. 363
Maroun, C.R., *see* Julius, N. 177
Marschang, P., *see* Dierich, M.P. 435
Maryanski, J.L., *see* Casanova, J-L. 391
Matzinger, P., *see* Fuchs, E. 153
Mazanec, M.B., Nedrud, J.G., Kaetzel, C.S. and Lamm, M.E., A three-tiered view of the role of IgA in mucosal defence 430
McCarthy, D.M., *see* Nygard, N.R. 53
McFarland, H., *see* Georgopoulos, C. 373
McLean, A., *see* Michie, C.A. 235
Melchers, F., Karasuyama, H., Haasner, D., Bauer, S., Kudo, A., Sakaguchi, N., Jameson, B. and Rolink, A., The surrogate light chain in B-cell development 60
Menger, M.D. and Lehr, H-A., Scope and perspectives of intravital microscopy – bridge over from *in vitro* to *in vivo* 519
Mescher, M.F., *see* O'Rourke, A.M. 183
Metzger, H., IUIS Report: International immunology 188
Metzger, H., *see* Beaven, M.A. 222
Meyaard, L., Schuitemaker, H. and Miedema, F., T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? 161
Michie, C.A. and McLean, A., Lymphocyte lifespan, immunological memory and retroviral infections (L) 235
Miedema, F., Acquired Immune Deficiency Syndrome (BR) 517
Meidema, F., *see* Meyaard, L. 161
Milstein, C., *see* Betz, A.G. 405
Mitchison, N., *see* Helbert, M.R. 340
Mitsuya, H., *see* Yarchoan, R. 303
Moll, H., Epidermal Langerhans cells are critical for immunoregulation of cutaneous leishmaniasis 383
Mond, J.J., *see* Snapper, C.M. 15
Morley, J., Immunopharmacology of asthma 317
Morrow, W.J.W., *see* Raychaudhuri, S. 344
Mosmann, T., *see* Wegmann, T.G. 353
Mountz, J.D. and Talal, N., Retroviruses, apoptosis and autogenes 532
Murase, N., *see* Starzl, T.E. 326

N
Nash, A.A., *see* Cambouropoulos, P.J. 144
Navia, M.A. and Peattie, D.A., Structure-based drug design: applications in immunopharmacology and immunosuppression 296
Naylor, M.S., *see* Burke, F. 165
Nedrud, J.G., *see* Mazanec, M.B. 430
Neuberger, M.S., *see* Betz, A.G. 405
Newman, W., *see* Gearing, A.J.H. 506
Nishimura, H., *see* Kimoto, M. 569
Noble, B.K., Immunological Aspects Of Renal Disease (BR) 97
Nygard, N.R., McCarthy, D.M., Schiffenbauer, J. and Schwartz, B.D., Mixed haplotypes and autoimmunity 53

O
O'Garra, A., Regulation and Functional Significance of T-Cell Subsets (BR) 570
O'Rourke, A.M. and Mescher, M.F., The roles of CD8 in cytotoxic T lymphocyte function 183
Ohishi, K., *see* Sugimoto, M. 190
Ohlin, M., *see* Borrebaeck, C.A.K. 477
Onyebujoh, P., *see* Rook, G.A.W. 568
Oosterwegel, M.A., *see* Clevers, H.C. 591
Oppenheim, J.J. and Gery, I., From lymphodrek to interleukin 1 (IL-1) 232
Osborne, B.A., *see* Schwartz, L.M. 582
Osmond, D.G., The turnover of B-cell populations 34
Owen, M.J., *see* Palmer, D.B. 460

P
Pabst, R. and Westerman, J., Lymphocyte lifespans revisited (L) 469
Palmer, D.B., Hayday, A. and Owen, M.J., Is TCRβ expression an essential event in early thymocyte development? 460
Pals, S.T., *see* Herrlich, P. 395

Paoletti, F., *see* De Simone, C. 515
Pardoll, D.M., Cancer vaccines 310
Parmiani, G., Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells 536
Peattie, D.A., *see* Navia, M.A. 296
Pechhold, K., *see* Kabelitz, D. 338
Perelson, A.S., *see* Kepler, T.B. 412
Platt, J.L., *see* Ihrcke, N.S. 500
Playfair, J., Heidikines (L) 469
Pochon, S., *see* Bonnefoy, J-Y. 1
Poggi, A., *see* Zocchi, M.R. 94
Pohl, T., *see* Kabelitz, D. 338
Ponta, H., *see* Herrlich, P. 395
Poussier, P. and Julius, M., Maturation of T cells in the intestinal epithelium (L) 140
Powrie, F. and Coffman, R.L., Cytokine regulation of T-cell function: potential for therapeutic intervention 270
Pozzilli, P., Signore, A., Williams, A.J.K. and Beales, P.E., NOD mouse colonies around the world – recent facts and figures 193
Protti, M-P., Manfredi, A.A., Horton, R.M., Bellone, M. and Conti-Tronconi, B.M., Myasthenia gravis: recognition of a human autoantigen at the molecular level 363
Pullen, A.M., Biological Significance of Superantigens (BR) 191

R
Racadot, E., Cord-blood lymphocyte populations (L) 189
Raftos, D.A. and Raison, R.L., Reply to Smith and Davidson (L) 92
Raison, R.L., *see* Raftos, D.A. 92
Rajewsky, K., B-cell lifespans in the mouse – why to debate what? 40
Ramsay, A.J., Ruby, J. and Ramshaw, I.A., A case for cytokines as effector molecules in the resolution of virus infection 155
Ramshaw, I.A., *see* Ramsay, A.J. 155
Raychaudhuri, S. and Morrow, W.J.W., Can soluble antigens induce $CD8^+$ cytotoxic T-cell reponses? A paradox revisited 344
Reiss, C.S. and Rouse, B.T., The current status of viral immunology 333
Rengaraju, M., *see* Trinchieri, G. 237
Ricordi, C., *see* Starzl, T.E. 326
Rider, C., Many cytokines and interleukins bind to glycosaminoglycans (L) 615
Ritter, M.A. and Boyd, R.L., Development in the thymus: it takes two to tango 462
Ritter, M.A., *see* Boyd, R.L. 445
Robertson, M.J., Biological Approaches to Cancer Treatment: Biomodulation (BR) 516
Rocha, B.B., *see* Freitas, A.A. 25
Rocha, B., Vassalli, P. and Guy-Grand, D., Reply to Poussier and Julius (L) 141
Rodriquez-Tarduchy, G., *see* Adorini, L. 285
Rolink, A., *see* Melchers, F. 60
Rook, G.A.W., Onyebujoh, P. and Stanford, J.L., T_H1/T_H2 switching and loss of $CD4^+$ T cells in chronic infections: an immunoendocrinological hypothesis not exclusive to HIV (L) 568
Rook, G.A.W., New meanings for an old word: adjuvanticity, cytokines and T cells (L) 95
Rose, N.R. and Bona, C., Defining criteria for autoimmune diseases (Witebsky's postulates revisited) 426
Rouse, B.T., *see* Reiss, C.S. 333
Ruby, J., *see* Ramsay, A.J. 155
Ruiz-Cabello, F., *see* Garrido, F. 491

S
Sakaguchi, N., *see* Melchers, F. 60
Salamero, J., *see* Wade, W.F. 539
Salk, J., *see* Atlan, H. 200
Salk, P.L., see Atlan, H. 200
Salmon, M., *see* Akbar, A.N. 526
Sandor, M. and Lynch, R.G., Lymphocyte Fc receptors: the special case of T cells 227
Santini, F. and Beaven, M.A., Nonselective actions of herbimycin A (L) 369
Savill, J., Fadok, V., Henson, P. and Haslett, C., Phagocyte recognition of cells undergoing apoptosis 131
Savill, J., *see* Akbar, A.N. 526
Savino, W., Villa-Verde, D. and Lannes-Vieira, J., Extracellular matrix proteins in intrathymic T-cell migration and differentiation? 158
Schendel, D.J., *see* Segurado, O.G. 45
Schiffenbauer, J., *see* Nygard, N.R. 53
Schlom, J., *see* Goldenberg, D.M. 5
Schönrich, G., *see* Arnold, B. 12
Schuitemaker, H., *see* Meyaard, L. 161
Schwartz, B.D., *see* Nygard, N.R. 53
Schwartz, L.M. and Osborne, B.A., Programmed cell death, apoptosis and killer genes 582
Segurado, O.G. and Schendel, D.J., Restricted TCR repertoire and disease (L) 45
Sell, S. and Hsu, P-L., Delayed hypersensitivity, immune deviation, antigen processing and T-cell subset selection in syphilis pathogenesis and vaccine design 576
Sercarz, E.E., *see* Lehmann, P.V. 203
Shaw, S., *see* Tanaka, Y. 111
Shearer, G.M., *see* Clerici, M. 107
Shirai, T., *see* Kimoto, M. 569
Sieper, J., *see* Kingsley, G. 387
Signore, A., *see* Pozzilli, P. 193
Simpson, S., T Lymphocytes: Structure, Function, Choices (BR) 420
Sloan-Lancaster, J., *see* Evavold, B.D. 602
Smith, L.C. and Davidson, E.H., Reply to Karp and reply to Cooper (L) 93
Snapper, C.M. and Mond, J.J., Towards a comprehensive view of immunoglobulin class switching 15
Söderqvist, T., How to write the recent history of immunology – is the time really ripe for a narrative synthesis? 565
Soltys, A., *see* Hay, F.C. 102
Spriggs, M.K., *see* Callard, R.E. 559
Stanford, J.L., *see* Rook, G.A.W. 568
Starzl, T.E., Demetris, A.J., Murase, N., Thomson, A.W., Trucco, M. and Ricordi, C., Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation 326
Steinman, L., *see* Wilson, D.B. 376
Stern, P.L., *see* Garrido, F. 491
Straus, D., *see* Fraser, J.D. 357
Sugimoto, M., Ohishi, K. and Ikawa, Y., Cell-mediated immunity to BLV relication: analogous to HIV immunopathogenesis? (L) 190
Swain, S.L., *see* Bradley, L.M. 197

T
Talal, N., *see* Mountz, J.D. 532
Tanaka, Y., Adams, D.H. and Shaw, S., Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes 111
Thielends, N.M., *see* Dierich, M.P. 435
Thomson, A.W., *see* Starzl, T.E. 326
Thorpe, C.J., Outsize peptides bulge out of the groove 51
Thorpe, P.E., *see* Vitetta, E.S. 252
Tomasi, T., Reply to Hanson and Brandtzaeg (L) 417
Torensma, R., A flaw in the detection of antigenic sites (L) 370
Trembleau, S., *see* Adorini, L. 285
Trinchieri, G., Interleukin-12 and its role in the generation of T_H1 cells 335
Trinchieri, G., Rengaraju, M., D'Andrea, A., Valiante, N.M., Kubin, M., Aste, M. and Chehimi, J., Producer cells of interleukin-12 (L) 237
Trowsdale, J., *see* Campbell, R.D. 349
Trucco, M. *see* Starzl, T.E. 326
Tsoukas, C.D. and Lambris, J.D., Expression of EBV/C3d receptors on T cells; biological significance 56
Tucek, C., *see* Boyd, R.L. 445
Tzantzoglou, S., *see* De Simone, C. 515

U
Uhr, J.W., *see* Vitetta, E.S. 252
Ulevitch, R.J., *see* Ziegler-Heitbrock, H.W.L. 121

V
Valiante, N.M., *see* Trinchieri, G. 237
Van Leuven, F., *see* De Strooper, B. 143
van de Winkel, J.G.J. and Capel, P.J.A., Human IgG Fc receptor heterogeneity: molecular aspects

and clinical implications 215
van Dijk, J., *see* Verdiun, C.M. 44
van Lier, R.A.W., *see* van Noessel, C.J.M. 8
van Noessel, C.J.M., Lankester, A.C. and van Lier, R.A.W., Dual antigen recognition by B cells 8
Vassallii, P., *see* Rocha, B. 141
Verduin, C.M., Hol, C., Bootsma, H.J., Verhoef, J. and van Dijk, H., Observations on constitutional resistance to infection (L) 44
Vergani, P., *see* Hooghe, R. 212
Verhoef, J., *see* Verduin, C.M. 44
Vidal, K., *see* Kaiserlian, D. 144
Villa-Verde, D., *see* Savino, W. 158
Vitetta, E.S., Thorpe, P.E. and Uhr, J.W., Immunotoxins: magic bullets or misguided missiles? 252
von Boehmer, H., *see* Groettrup, M. 610

W
Wade, W.F., Davoust, J., Salamero, J., André, P., Watts, T.H. and Cambier, J.C., Structural compartmentalizations of MHC class II signalling function 539
Waldmann, H. and Cobbald, S., The use of monoclonal antibodies to achieve immunological tolerance 247
Waldann, T.A., The IL-2/IL-2 receptor system: a target for rational immune intervention 264
Watts, T.H., *see* Wade, W.F. 539
Webb, D.R., *see* Green, D.R. 523
Wegmann, T.G., Lin, H., Guilbert, L. and Mosmann, T.R., Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a T_H2 phenomenon? 353
Weiss, A., *see* Fraser, J.D. 357
Westermann, J., *see* Pabst, R. 469
Whelan, A., Of furphys, and facts that are fugacious (L) 142
Whelan, A., The Seeds of Time – a Biography of MacFarlane Burnet (BR) 46
Whetton, A., Concise Reviews in Clinical and Experimental Haematology (BR) 239
Whitmore, A.C., *see* Haughton, G. 84
Whitmore, A.C., *see* Haughton, G. 88
Wiktor-Jedrzejczak, W., Eosinophil development (L) 238
Williams, A.J.K., *see* Pozzilli, P. 193
Wilson, D.B. Steinman, L. and Gold, D.P., The V-region disease hypothesis: new evidence suggests it is probably wrong 376
Wilson, T., *see* Boyd, R.L. 445
Winslow, C.M., *see* Wong, R.L. 69
Winter, G. and Harris, W.J., Humanised antibodies 243
Wong, R.L., Winslow, C.M. and Cooper, K.D., The mechanisms of action of cyclosporine A in the treatment of psoriasis 69
Woodland, D.L. and Blackman, M.A., How do T-cell receptors, MHC molecules and superantigens get together? 208
Wortis, H., The nature of B-cell subpopulations: comment 89
Wrenshall, L.E., *see* Ihrcke, N.S. 500

Y
Yarchoan, R., Mitsuya, H. and Broder, S., Challenges in the therapy of HIV infection 303

Z
Zbinden, G., Biologic Markers in Immunotoxicology (BR) 240
Ziegler-Heitbrock, H.W.L. and Ulevitch, R.J., CB14: Cell surface receptor and differentiation marker 121
Ziegner, M., *see* Berek, C. 400
Zlotnik, A., *see* Godfrey, D.I. 547
Zocchi, M.R. and Poggi, A., NCAM and lymphocyte adhesion in leukocyte adhesion deficiency (LAD) syndrome (L) 94
Zöller, M., *see* Herrlich, P. 395
Zouali, M., Kalsi, J. and Isenberg, D., Autoimmune diseases – at the molecular level 473

Subject Index

References are to page numbers.
The suffix (L) = Letter to the Editor.
Alphabetization is letter-by-letter e.g.
T cells
T-cell vaccination

A
Acetylcholine receptor (AChR) 363
Acquired immune deficiency syndrome *see* AIDS
Activation antigens
  swine leucocyte antigens 147
ADCC *see* antibody-dependent cellular cytotoxicity
Addison's disease 116
Adhesion *see* cell adhesion molecules
Adjuvant arthritis 476
Adjuvants
  activity 281
  alternatives to Freund's complete adjuvant 283
  clinical perspectives 283
  cytotoxic T-cell responses 346
  tumour vaccines 311
Affinity maturation 400
  cyclic re-entry of germinal centre B cells 412
  immunoglobulin *V* genes 405
Agammaglobulinaemia 554, 559
AIDS (acquired immune deficiency syndrome) *see also* HIV
  disease progression in different HLA-DR genotypes 417 (L)
  drug therapies 303, 343
  humanized antibodies 245
  soluble CD14 serum levels 515 (L)
  T-cell vaccination 200, 615 (L)
Airway hyperreactivity *see* asthma
Allergic disease
  cytokine manipulation of T-cell subsets 273
  IgE-binding protein (εBP) 486
  IgE regulation 1
Allograft rejection
  IL-2R as a target for immunotherapy 268
  immunosuppressive agents 267
Altered peptide ligands 602
Alum 283
Alzheimer's disease 143 (L)
Animal models
  autoimmune disease 427, 475
  intravital microscopy 519
  β_2-microglobulin deficiency 333
  reactive arthritis (ReA) 390
Antibody-based therapy
  immunotoxins *see* immunotoxins
  mAbs *see* monoclonal antibodies
Antibody-dependent cellular cytotoxicity (ADCC)
  FcγR mediation 217, 220
  xenotransplantation 477, 481
Antibody hypermutation *see* hypermutation
Antibody-mediated autoimmunity 323
Anti-Gal activity 477, 480
Antigen presentation
  altered peptide ligands 602
  cytotoxic T-cell responses induced by soluble antigens 344
  defects 543
  MHC class II 539
  enhancement by FcγR 217, 220
  peptide–MHC complexes 285
  Rab proteins 442
  reactive arthritis (ReA) 389
  Rho proteins 440
  viral immunology 333
Antigen-presenting cells
  CsA, effects of 72
  dysfunction in HIV infection 161, 341
  heparan sulphate proteoglycan in immune system-blood vessel interactions 112, 500, 615 (L)
  intestinal epithelium 144 (L)
Antigen processing 333
  peptide–MHC complexes 3, 285
Antigen recognition
  altered peptide ligands 602
  B cells 8, 515 (L)
  signal transduction events leading to T-cell lymphokine expression 357
Antigenic site detection 370 (L)
Antigen-specific tumour vaccines 315 *see also* tumour cells
Apoptosis (programmed cell death) 126, 585
  activation-induced T-cell death 338
  autoimmune disease 533
  bcl-2 expression 527
  genetic regulation 128, 585
  morphology-function correlations 127
  phagocyte recognition of apoptotic cells 131
  physiological process 589
  signal transduction 586
Arthritis *see* adjuvant arthritis; reactive arthritis; rheumatoid arthritis
Asthma 317
Atherosclerosis
  blocking the action of IL-1 262
Atopy 318
'Autogenes' 533
Autoimmune disease
  animal models 427, 475
  apoptosis 533
  autoantibodies 426
  autoimmune diabetes 49
  cytokine manipulation of T-cell subsets 273
  defining criteria 426
  genetically induced disease models 429
  genetic mechanisms 532
  hsp60 115
  humanized antibodies 245
  IL-2 therapy 266
  immunointervention 475
  immunosuppression by monoclonal antibodies 247
  see also immunosuppression
  intrathymic selection and peripheral T-cell tolerance 473
  isolation of autoantibodies or autoreactive T cells 429
  MRL/*lpr* model 533
  myasthenia gravis *see* myasthenia gravis
  NOD mice *see* non-obese diabetic mice
  role of heat shock proteins 373
  role of mixed haplotypes 53, 569 (L)
  targets of autoimmune attack 474
  T cells specific for autoantigens in healthy and diseased individuals 426
  TCR repertoire 473
  tumour immunity 536
  viral factors 536
  Witebsky's postulates 426
Autoimmune encephalomyelitis 476, 607
Autoimmune T cells
  anergy and activation 203
  reversing the immunostimulatory environment 206
  T-cell mediated suppression 523
Azathioprine 323
Azidothymine 303
AZT 303

B
B7 539, 545
B7 gene 313
  costimulation of T-cell responses to tumour antigens 484
Bacterial infection
  FcγR-mediated responses 220
  reactive arthritis (ReA) 387
Bacterial toxins 253
  lipopolysaccharide endotoxins 275
B-cell antigens receptor (BCR) 8, 515 (L)
B cells
  antibody-mediated autoimmune disease 323 *see also* autoimmune disease
  antigen presentation 539
  B-1 cells 79
  birth, death and survival in the bone marrow 34
  CD40 ligand (CD40L) 559
  CR2 receptors 57
  cyclic re-entry in the germinal centre 412
  developmental similarities with thymocytes 461
  diversification of immune responses 151, 153
  dual antigen recognition 8, 515 (L)
  hyper-IgM syndrome (HIGM1) 561
  idiotypy 120
  IL-12 production 335

immunoglobulin class switching 15
immunosuppressive treatment for myasthenia gravis 367
independent regulation of the numbers of memory B cells and mature virgin B cells of the RF and MZ pools 31
interaction with T cells 539
lifespan 29, 40
maturation of the immune response 400, 412
MHC class II signalling *see* MHC class II
murine B-cell lineages 79
population dynamics in peripheral lymphoid tissues 35
recruitment of virgin and memory B cells 32
selection and differential survival 38
surface Ig as a possible ligand for T-cell FcR 229
surrogate light chain in early development 60
swine leucocyte antigens 147
utilization of *V*-regions in the adult 38
X-linked agammaglobulinaemia 554
BCG (Bacille-Calmette-Guerin) vectors 580
bcl-2 gene 129
apoptosis 582
autoimmune disease 534
T-cell memory development and longevity 526
Benign tumours 492 *see also* tumour cells
ϵBP 486
Biographies 565
Blood donation 328
Blood vessels
heparan sulphate proteoglycan in immune system–blood vessel interactions 112, 500, 615 (L)
Bone marrow
birth, death and survival of B cells 34
disruption of B-cell development in mice carrying deficient λ_5 gene 65
donation 328
Bovine leukaemia virus (BLV) 190
British Society for Immunology
epitope mapping workshop 102
Bronchospasm *see* asthma
Btk protein 556

C
C3d receptors 56
C3dg receptors 9, 515 (L)
Calcineurin
phosphatase activity inhibited by immunophilin–drug complexes 292
phosphatase inhibition by FK506 and cyclosporin 300, 358
Calcium transport pathways
FcϵRI signalling 224
FK506 and cyclosporin as molecular probes 290
Calmodulin 292, 358
cAMP 541
Cancer *see also* tumour cells
CD44 and metastasis 101, 395
humanized antibodies 245
IL-2 therapy 266
monoclonal antibodies 422
preventing anti-Gal activity of mouse mAbs in cancer therapy 477
radioimmune conjugates 5
Cancer vaccines 311, 538
see also tumour-specific antigens
Carcinoma *see* cancer; tumour cells
CD3–TCR complex 177, 184, 338, 539
altered peptide ligand recognition
functional uncoupling: the role of lck 179
recognition of peptide/MHC 597
transcription factors *see* transcription control
CD4
antigen receptor signalling 177
blockade 286
distinct roles for CD4 and CD8 as co-receptors 178
functional role of lck 179
immunosuppression by monoclonal antibodies 249
sequestration hypothesis of CD4/CD8 signalling 180
$CD4^+$ T cells 151
adjuvants *see* adjuvants
antitumour response 311
destruction in HIV infection 161, 303, 340, 568 (L), 615 (L)
early development 552
IL-12 and generation of T_H1 cells 237 (L), 335
immunological memory *see* memory T cells
immunosuppressive treatments for myasthenia gravis 367
proposed AIDS vaccine 201, 615 (L)
subsets 270
TCRα rearrangement and expression 552
TCRβ expression in early development 460, 610
CD5 81, 84, 87, 547
CD8
antigen receptor signalling 177
distinct roles for CD4 and CD8 as co-receptors 178, 184
functional role of lck 179
immunosuppression by monoclonal antibodies 249
pathways for TCR and CD8-dependent signalling 184
role in the cascade of adhesion and signalling events 186
sequestration hypothesis of CD4/CD8 signalling 180
structure and binding to MHC class I 183
variable roles for CD8 during CTL life 187
$CD8^+$ cytotoxic T cells (CTLs) 183
antitumour response 311
antiviral role 155
early development 552
MHC-peptide interactions 51
responses induced by soluble antigens 344
TCRα rearrangement and expression 552
TCRβ expression in early development 460, 610
CD14 121
serum levels in AIDS 515 (L)
soluble CD14 123, 515 (L)
CD19
CR2–CD19 complex 9
CD21 1, 9, 56, 515 (L)
CD23
binding to CD21 1
FCϵRII 229
structure, distribution and function 1
CD25
early T-cell development 547
CD28
costimulation of T-cell responses 484
signal transduction events leading to T-cell lymphokine expression 360
CD40 540
ligand (CD40L) 559
CD44
cancer metastasis 101, 395
early T-cell development 547
splice variants carrying exon v6 396
swine leucocyte antigens 147
CD45
activation of $CD4^+$ and $CD8^+$ T cells 179
immunological memory 340, 235 (L), 526
swine leucocyte antigens 147
cDNA
analysis of FcγR structure 216
CDR (complementarity determining regions)
antibody hypermutation 405
humanized antibodies 243
CDR3 region
encephalitogenicity 377
TCR–MHC interactions 600
TCR–peptide contact 597
Cell adhesion molecules 99
CD44 and cancer metastasis 101
heparan sulphate proteoglycan in immune system–blood vessel interactions 112, 500, 615 (L)
role in the immune system 99
soluble isoforms 506, 509
Cell-mediated immunity
bovine leukaemia virus and analogies with HIV 190
Fc receptors *see* Fc
pregnancy 353
Central nervous system (CNS)
effects of IL-1 172
Chaperones 373
Chimerism
in transplantation 326
Chordates, primitive 91 (L)
Chronic active hepatitis 116
Ciliary neurotrophic factor (CNTF) 335
Circulating adhesion molecules 506
measurement 509
Cirrhosis, primary biliary 116
Clinical trials
adjuvants 281
efficacy of monoclonal antibodies 421
HIV therapy 303
immunotoxins 255
Clonotypes 119, 513
c-myb gene 533
c-myc gene 128, 587

CNTF (ciliary neurotrophic factors) 335
Cold agglutinin 120
Colony stimulating factors *see* CSFs
Complementarity determining regions *see* CDR
Complement deficiency 475
Complement system
  dual antigen recognition by B cells 8
  interaction between HIV-1 and human complement 435
Cord-blood lymphocyte populations 189
C1q receptors 438
CR2 *see* CD21
CsA *see* cyclosporin A
CSFs (colony stimulating factors) 18
  formation by human monocytes 21
CTLs *see* cytotoxic T cells
Cutaneous immunobiology 75
CV1/EBNA cells 559
Cyclooxygenase/lipoxygenase inhibitors 260
Cyclophilins 291
Cyclophosphamide 323
Cyclosporin 290
  asthma therapy 318
  improvement by structure-based drug design 300
  inhibition of IL-2 gene expression 358
  toxicity 299, 324
Cyclosporin A (CsA) 369 (L)
  effect on thymic microenvironment 462
  immunosuppression 267, 323
  psoriasis, treatment of 69
Cytokines 149, 333 *see also* interleukins
  adjuvanticity 283
  antiviral activity 155
  autoimmune T cell regulation 205, 523
  CsA, effects of 71
  Cytokine Wall Chart 165
  discovery of IL-1 232, 469 (L)
  gene-transduced tumour vaccines 313
  immunoglobulin class switching 15
  maternal–fetal relationship 353
  polarized secretion 441
  proteoglycans and adhesion molecules 111, 615 (L)
  regulation of CSF (colony stimulating factor) synthesis 18
  regulation of T-cell function 270
  secretion by naive cells and memory cells 198
  signal transduction events leading to T-cell lymphokine expression 357
  skin immune system 76
  T_H cell development 95 (L)
  thymocyte development 464
Cytoskeleton organization 440
Cytotoxic T cells (CTLs) 183
  adjuvants *see* adjuvants
  antitumour response 311
  antiviral role 155
  effects of IL-12 337
  MHC–peptide interactions of MHC class I molecules 51
  responses induced by soluble antigens 344
Cytotoxicity
  FcR mediation 217, 220
  immunotoxins 254

D
Dehydroepiandrosterone (DHEA) 568 (L)
Delayed-type hypersensitivity (DTH)
  in pregnancy 353
  protection against syphilis 576
Dendritic cells 330
  HIV infection 341
  Langerhans cells *see* Langerhans cells
  MHC class I-restricted CTL induction 346
Determinant spreading 203
  autoimmune T cells *see* autoimmune T cells
Deuterostomes 91 (L)
Diabetes
  animal models 475
  autoimmune disease 49
  insulin-dependent diabetes mellitus (IDDM) 322
  NOD mice *see* non-obese diabetic mice
  sequence homologies between hsp60 and autoantigens 115
Diphtheria toxin 253, 268
Drug development
  HIV therapies 303, 343
  immunosuppression *see* immunosuppression
  structure-based drug design (SBDD) 296
drug resistance 324

E
εBP 486
EBV (Epstein–Barr Virus) 56
Echinoid immune system 91 (L)
ECM *see* extracellular matrix
ELISA (enzyme-linked immunoassay)
  anti-idiotypic antibodies 423
  circulating adhesion molecules 509
Encephalomyelitis 376, 476, 607
Endocrine system
  autoimmune disease 533
  effects of IL-1 171
  growth hormone and prolactin in haemopoiesis 212
  T_H1/T_H2 switching in HIV and tuberculosis 568 (L)
Endothelial cells
  CsA, effects of 72
  proteoglycans and adhesion-inducing cytokines 111, 500, 615 (L)
  soluble adhesion molecules 506
Endotoxins 275
Enzyme inhibitors 296
Enzyme-linked immunoassays *see* ELISA
Eosinophils 238 (L)
  asthma 318
Epidermal Langerhans cells *see* Langerhans cells
Epitope mapping 102, 203
E-selectin 508
ETn retrotransposon sequences 533
Ets genes 593
Experimental allergic encephalomyelitis (EAE) 376, 476
Extracellular matrix (ECM) 450
  ECM proteins in intrathymic T-cell migration and differentiation 158

F
Fas gene, and gene product 129, 533, 582
Fcγ RI, II and III
  structure and function 215
  on T cells 227
FcεRI
  signalling 222
  on T cells 227
FcεRII *see* CD23
Feto-placental unit
  T_H2 cytokine interactions 353
Fibronectin (FN) 450
FK506 267
  effect on thymic microenvironment 463
  improvement by structure-based drug design 300
  inhibition of IL-2 gene expression 292, 358
  intracellular signal transduction 290
  toxicity 299
FK binding proteins (FKBP) 291, 300
Freund's complete adjuvant 283
Fungal glycans 275

G
GAGs *see* glycosaminoglycans
Galactose-binding lectins 486
α-galactosyl epitopes 480
Gal α1-3Gal glycosylation 477
Gamma interferon *see* IFN-γ
GATA sequence motifs 592
Gene-transduced tumours 312
Germinal centre
  cyclic re-entry of B cells 412
  maturation of the immune response 401
Glomerulonephritis 116
Glucocorticoids 568 (L)
  asthma 319
Glycoimmunology 104
Glycosaminoglycans (GAGS) 112, 615 (L)
GM-CSF (granulocyte-macrophage CSF) 18
gp120 568 (L) *see also* HIV
  anti-HIV gp120 T-cell vaccination 201, 615 (L)
G proteins 225
  Rab subfamily 442
  Rho subfamily 440
Grafts *see also* organ transplantation
  immunotherapy 268
  immunosuppression by monoclonal antibodies 249
  immunosuppressive agents 267
  xenotransplantation 480
Graft versus host disease (GVHD)
  donor cell chimerism 330
  immunotherapy 268
Granulocytes *see* eosinophils, mast cells, neutrophils
Graves' disease 322
Growth hormone (GH) 212
GTP-binding proteins *see* G-proteins
GVHD *see* graft versus host disease

H
Haematopoietic stem cells (HSC)
  B-cell lineages in the mouse 79
Haemophilus influenzae 220
Haemopoietic growth factors 212

Hashimoto's thyroiditis 116
Hassall's corpuscles (HC) 449
Heat shock protein (hsp)
role in multiple sclerosis and other autoimmune diseases 373
sequence homologies between hsp60 and autoantigens 115
targets of autoimmune attack 474
Heat stable antigen (HSA) 539, 547
Helper T cells *see* T_H cells
Hema-/hemo- *see* haema-/haemo-
Heparan sulphate proteoglycan
role in immune system–blood vessel interactions 112, 500, 615 (L)
Hepatitis, chronic active 116
Herbimycin A 369 (L)
History of immunology 565
HIV (human immunodeficiency virus) 334 *see also* AIDS
analogies with bovine leukaemia virus (BLV) 190
antigen-presenting cell defects 161, 341
$CD4^+$ T-cell destruction 161, 303, 340, 568 (L)
disease progression in different HLA-DR genotypes 417 (L)
drug therapies 303
interaction between HIV-1 and human complement 435
T-cell anergy 161
proposed T-cell vaccination 200, 615 (L)
T_H 1-T_H 2 imbalance 107, 161, 304, 417 (L), 568 (L)
uninfected lymphocyte lifespans 235 (L)
HLA-B27
role in reactive arthritis (ReA) 387
HLA (human leucocyte antigen) genes 491
AIDS progression in different HLA-DR genotypes 417 (L)
antigen processing and presentation 3
associations with tumour invasiveness and differentiation 493
expression in normal tissues 491
HLA and disease 4
HLA-DR antigens in premalignant and malignant lesions 493
mechanisms affecting gene expression in tumours 495
MHC evolution 4
HMG (High Mobility Group) box proteins 591
Homeobox proteins 594
Homeostasis 25
Hormone-related autoimmune disease 533
Host anti-mouse antibody response (HAMA) 477
HSC (haematopoietic stem cells)
B-cell lineages in the mouse 79
Hsp *see* heat shock proteins
Human immunodeficiency virus *see* HIV
Humanized antibodies 243
IL-2R 268
Human leucocyte antigens *see* HLA genes
Human T-cell leukaemia virus (HTLV)
IL-2R antibodies 268
Humoral immunity
cyclic re-entry of germinal centre B cells 412
Fc receptors *see under* Fc
hypermutation of immunoglobulin *V* genes 405
IgA and mucosal defence 430
maturation of the immune response 400
pregnancy 353
Hybridoma technology 243, 400
Hyper-IgM syndrome (HIGM1) 560
Hypermutation
cyclic re-entry of germinal centre B cells 412
immunoglobulin *V* genes 405
maturation of the immune response 400
nucleotide substitution preferences 405
Hypothalamus
effects of IL-1 172

I
ICAM-1 506
Idiotypy 119, 513
IEL (intraepithelial lymphocytes) 140 (L)
IFN-γ (gamma interferon) 20
activation of monocyte-macrophages 22
antiviral role 155
decline in production in HIV infection 107, 110, 161, 304
immunoglobulin class switching 15
induction by IL-12 336
maternal–fetal relationship 353
secretion by naive cells and memory cells 198
IFN inducers 275
IgA 416 (L)
role in mucosal defence 430
IgE
allergic asthma 318
regulation through CD23 1
εBP in allergic inflammation 486
IgG
agalactosyl glycoforms 475
Fc receptors *see* FcγR
glycosylation 105
IgM
hyper-IgM syndrome (HIGM1) 560
Ikaros 593
IL-1 171
central neural effects 172
differential production of IL-1 and IL-1Ra 262
discovery 232, 469 (L)
neuroendocrine and immune integration 175
receptor activation and signal transduction 172, 539
soluble receptors 261
subtypes and receptors 171
therapeutic inhibition 260
IL-2
anti-tumour response 538
antiviral activity 155
bcl-2 expression 529
decline in production in HIV infection 107, 161, 304, 417 (L)
early T-cell development 547
maternal–fetal relationship 353
promoter activity 359
secretion by naive cells and memory cells 198, 526
structure of IL-2/IL-2 receptor system 264
therapeutic uses 266
transcriptional activation inhibited by FK506 and cyclosporin 292, 358
IL-3 19
adhesion triggering 112, 615 (L)
IL-4
allergic asthma 318
CSF (colony stimulating factor) formation 22
immunoglobulin class switching 15
increased production in HIV infection 108, 304
maternal–fetal relationship 354
polarized secretion 441
secretion by naive cells and memory cells 198
IL-5
maternal–fetal relationship 354
IL-6 335
increased production in HIV infection 304
maternal–fetal relationship 354
IL-7 452, 550
adhesion triggering 112, 615 (L)
IL-8
adhesion triggering 111, 615 (L)
IL-10
increased production in HIV infection 108, 304
maternal–fetal relationship 354
IL-12
early T-cell development 550
generation of T_H1 cells 237 (L), 335
producer cells 237 (L)
Immune complex clearance 475
Immunodeficiency
X-linked *see* X-linked immunodeficiencies
Immunoglobulin class switching 15
Immunoglobulin genes
hypermutation 405
Immunoglobulins *see also* Ig
crosslinking membrane immunoglobulin and CR2 8, 515 (L)
intravenous (IVIG) 514, 516 (L)
phenotype of Ig gene products 120
surrogate light chain in B-cell development 60
Immunoglobulin superfamily adhesins 506
Immunological memory *see* memory B cells; memory response; memory T cells
Immunology
biographies 566
history 565
Immunomodulation
adjuvants *see* adjuvants
immunostimulants *see* immunostimulants
immunosuppression *see* immunosuppression
structure-based drug design (SBDD) 296
Immunopharmacology 241
asthma *see* asthma
structure-based drug design 296
Immunophilins 292, 300

Immunostimulants
chemically defined/nonspecific 275
Immunostimulating complexes (ISCOMS) 282, 346
Immunosuppression 322
activation of regulatory T cells 287
antibody-mediated diseases 323
CD4 blockade 286
cyclosporin A (CsA) 267, 290, 299, 323
drug resistance 324
FK506 267, 290, 299
hazards 325
monoclonal antibodies 247, 421
myasthenia gravis, potential treatments for 367
organ transplantation *see* organ transplantation
rapamycin 267, 291, 299
selective immunosuppression 285
structure-based drug design (SBDD) 296
T-cell mediated diseases 323
thymic microenvironment 462
tolerance induction 287
Immunotoxins
design and use in immunotherapy 252
Infectious diseases
cutaneous leishmaniasis 383
cytokine manipulation of T-cell subsets 273
FcγR-mediated resistance 220
humanized antibodies 245
monoclonal antibodies 422
reducing interleukin-1 activity 262
Inflammatory arthritis
ReA *see* reactive arthritis
Inflammatory mediator release
FcγR mediation 217
Inflammatory response 100
asthma 317
cytokine manipulation of T-cell subsets 273
heparan sulphate proteoglycan 112, 500, 615 (L)
soluble mammalian lectins in allergic inflammation 486
Insulin dependent diabetes mellitus (IDDM) 322
see also non-obese diabetic mouse
Integrins 100
soluble 506
tumour metastasis 395
vitronectin receptor 132
γ-interferon *see* IFN-γ
Interleukins *see also* IL
signal transduction events leading to T-cell lymphokine expression 358
International Union of Immunological Societies (IUIS) 188
Intestinal epithelial cells 144 (L)
Intestinal intraepithelial lymphocytes *see* IEL
Intercellular adhesion molecules *see* ICAM-1
Intravenous immunoglobulin *see* IVIG
Intravital microscopy 519
Invasive carcinomas 493
see also tumour cells
IVIG (intravenous immunoglobulin) 514, 516 (L)

J
Juvenile onset diabetes mellitus *see* IDDM

K
Keratinocytes
CsA, effects of 70
cytokine production 76
Kidney disease
glomerulonephritis 116, 117
lupus nephritis 53
Kidney transplantation 327

L
λ_5 surrogate light chain 60
Lactose-binding lectins 486
Laminin (LN) 450
Langerhans cells 75
CsA, effects of 72
HIV infection 341
role in *Leishmania* infection 384
lck ($p56^{lck}$)
CD4 and CD8 as co-receptors 177
functional uncoupling of TCRαβ and the CD3 complex 179
Lectins
phagocyte recognition of apoptotic cells 131
soluble mammalian lectins in allergic inflammation 486
Lef-1 591
Leishmania infection
early phase 383
regulation of immunity by IL-12 337
role of Langerhans cells 384
Leucocyte activation
asthma 319
Leucocyte adhesion *see* cell adhesion molecules
Leucocyte adhesion deficiency (LAD) syndrome 94 (L)
Leukaemia
blocking the action of IL-1 in myelogenous leukaemia 262
role of CD14 in myelomonocytic leukaemias 124
Light (L) chain
B-cell development 60
Lipid A analogs 276, 282
Lipopolysaccharide endotoxins 275
Lipopolysaccharides (LPS)
CD14 binding 121, 515 (L)
Live recombinant vaccines 344
Liver transplantation 327
Lower deuterostomes 91 (L)
Lpr-associated defects 533, 588
LPS *see* lipopolysaccharides
L-selectin 506
Lupus nephritis 53
Lymphocyte activation
two signal model 235 (L)
Lymphocyte adhesion 94 (L)
see also cell adhesion molecules
Lymphocyte development
cell adhesion molecules 101, 229
Lymphocyte lifespans 25, 469 (L)
B-cell lifespan 29
B-cell lifespans in the mouse 40
B-cell population dynamics in bone marrow and peripheral lymphoid tissues 35
model for turnover and selection 39
recruitment of newly-produced virgin and memory B cells 32
T cells 235 (L)
V-regions in the adult 38
Lymphokines
discovery of IL-1 232
polarized secretion 441
signal transduction events leading to T-cell lymphokine expression 357
Lysosomal enzyme release
FcγR mediation 217, 220

M
mAbs *see* monoclonal antibodies
α2-macroglobulin (α2M) 143 (L)
Macrophages
history of IL-1 discovery 232
IL-12 production 335
immunoglobulin class switching 16
Leishmania infection 383
MHC class I-restricted CTL induction 347
swine leucocyte antigens 147
Major histocompatibility complex *see* MHC
Malignant tumours 493 *see also* tumour cells
Marginal zone (MZ) B cells 30, 400, 405, 412
Mast cells
CsA, effects of 73
IgE-mediated activation 317
Maternal–fetal relationship
T_H2 cytokine interactions 353
Maturation of the immune response 400
cyclic re-entry of germinal centre B cells 412
immunoglobulin *V* genes 405
M-CSF (macrophage CSF) 18
MDPs (muramyl dipeptides) 275, 282
Medullary thymocytes 449, 462
Mel-14 547
Melanoma 537
Memory B cells 31, 400, 412
Memory T cells 235 (L)
activation requirements of T-cell subsets 197
association between low bcl-2 expression, apoptosis and memory 527
CD45 and immunological memory 340
$CD45RO^+$ T cells *in vivo* 526
cytokine secretion 198
frequency and longevity after priming 197
influence of stromal microenvironments on survival 529
T_H1- and T_H2-like memory cells 198
Memingococcal disease 220
Metastasis
CD44 and cancer 101, 395
MG *see* myasthenia gravis
MHC (major histocompatibility complex)
αβ TCR interactions 597, 600
antigen processing and presentation 3, 344
class I gene expression in tumours 495
crystalline structures 333

evolution 4
genetic alteration of tumours 312
map of human MHC 349
TCR–MHC interaction in superantigen activity 208
MHC blockade 286
MHC class I
HLA-B27 and reactive arthritis (ReA) 387
interaction with naive lymphocytes 13
MHC–peptide interactions 51
MHC class II
antigen presentation 539
cytoplasmic domains 542
defects in antigen presentation 543
mixed haplotypes and autoimmunity 53, 569 (L)
sequence homologies between hsp60 and autoantigens 115
signal transduction 542
Microbially derived immunostimulants 275
Microchimerism *see* chimerism
β_2-microglobulin deficiency 333
Microscopy, intravital 519
MIg (membrane immunoglobulin)
dual antigen recognition 8, 515 (L)
MIP-1β 111, 615 (L)
Molecular chaperones 373
Molecular modelling
structure-based drug design (SBDD) 297
Monoclonal antibodies (mAbs)
analysis, development and production 424
anti-Gal activity of mouse mAbs in cancer therapy 477
humanized antibodies 243
imaging and therapy with radioimmunoconjugates 5
immunosuppression 247, 421, 476
immunotoxin ligands 252
infectious diseases 422
radiolabelling 269
therapeutic concerns 421
Monocyte-macrophages 18, 21
CSFs 18
IL-12 production 335
Monophosphoryl lipid A 282
Mouse haplotypes 53
MRL/*lpr*-associated defects 533, 588
MS *see* multiple sclerosis
Mucosal immune system 416 (L)
role of IgA 430
Multiple sclerosis (MS) 116, 323
autoimmune T-cell repertoire 203
role of heat shock proteins 373
V-region disease hypothesis 376
Muramyl dipeptides (MDPs) 275, 282
Myasthenia gravis (MG) 322
autoimmune response against the muscle nicotinic acetylcholine receptor (AChR) 363
potential immunosuppressive treatments 367
Mycobacterium tuberculosis 200
Myelin basic protein (MBP) 376, 476
Myelogenous leukaemia
blocking the action of IL-1 262

N
Naive T cells 13 *see also* memory T cells
cytokine secretion 198
Natural killer cells *see* NK cells
NCAM (neural cell adhesion molecule) 94 (L)
Necrosis 582
Neoplasia *see* cancer; tumour cells
Neuroendocrine system *see* endocrine system
Neuropathology
role of heat shock proteins 374
Neutrophils
CsA, effects of 72
NF-AT (nuclear factor of activated T cells) 292
NK cells
antiviral role 155
effects of IL-12 335
IFNγ in Ig class switching 16
Non-obese diabetic (NOD) mice
colony effects on disease incidence 193
environmental conditions/housing and maintenance of breeding stock 195
tolerance induction 574
Nonspecific urethritis 387
Nuclear magnetic resonance (NMR)
structure-based drug design (SBDD) 296
Nucleoside analogues 343
Null cells
swine leucocyte antigens 147

O
Oncogenes 496, 533
see also tumour cells; tumour-specific antigens
Opsonic phagocytosis
dual antigen recognition by B cells 8, 515 (L)
Organ transplantation *see also* grafts
cell augmentation with donor bone marrow, splenocytes or blood 328
host and graft chimerism and other interactions 329
immunological interface 329
immunosuppression by monoclonal antibodies 249
kidney 327
liver and other organs 327
xenografts 480

P
p53 534
p53 gene 129
p55 63
p56^{lck} 461, 551
Paracrine growth and differentiation factors 212
Parasitic infection
Leishmania see Leishmania infection
Pemphigoid 116
Peptide binding
altered peptide ligands 602
MHC–peptide interactions of class I molecules 51
T-cell receptor recognition of MHC/peptide complexes 597
Peptide transporters 333
Peptidyl prolyl *cis-trans* isomerase 290
Peripheral T-cell death 126, 338, 582
Peripheral tolerance 12, 473, 573
suppressor T cells 523
tumour immunity 536
Phagocytosis
FCγR mediation 217, 219
IL-12 production 335
Leishmania infection 383
MHC class I-restricted CTL induction 346
recognition of apoptotic cells 131
Phosphodiesterase isoenzyme inhibitors 319
Phospholipases (PLs)
FCεRI-mediated activation 223
Phosphorylation 357
Pigs
leucocyte antigens 147
Pituitary secretory proteins 212
PKC *see* protein kinase C
PLA_2 223
Plant toxins 253
Plasma membrane 542
PLC 224
PLD 224
Pre-B cells 65
Precursor T cells 547 *see also* thymus
Pregnancy
T_H2 cytokine interactions in the maternal–fetal relationship 353
Pre-T-cell receptors 610
see also thymus; T-cell receptors
Primary biliary cirrhosis 116
Programmed cell death *see* apoptosis
Prolactin (PRL) 212
Prostaglandin 20
blocking the action of IL-1 261
Protein engineering
humanized antibodies *see* humanized antibodies
immunotoxins *see* immunotoxins
Protein kinase C (PKC) 358, 540
Protein phosphorylation 357
Protein tyrosine kinases (PTKs) 8
see also p56^{lck}; signal transduction
Proteoglycans
adhesion triggering 111, 615 (L)
in immune system-blood vessel interactions 112, 500, 615 (L)
P-selectin 507
Psychoneuroimmunology 532
Pseudomonas exotoxin (PE) 253, 268
Psoriasis
treatment with cyclosporin A 69

Q
QS-21 346
Quil A 346

R
RA *see* rheumatoid arthritis
Rab proteins 442
Radioimmunotherapy (RAIT) 5
Radiolabelling 269
Rapamycin 267, 291
toxicity 299
Rap proteins 440
Reactive arthritis (ReA) 387
Recombinant vaccinia viruses (rVV) 155, 344
vaccination against syphilis 579
Renal disease
glomerulonephritis 116, 117
lupus nephritis 53
Retrotransposons 533
Retroviruses 235 (L)

autoimmune disease 532
Rheumatoid arthritis (RA)
glycoimmunology 104
humanized antibodies 245
sequence homologies between hsp60 and autoantigens 116
targets of autoimmune attack 474
TCR repertoire 473
Rheumatoid factors 119
Rho proteins 440
Rotamase 291, 300

S
Saponins 282, 346
Scleroderma 116
Secretory IgA 416 (L), 417 (L)
Selectins 506
Self-antigen
autoimmune T cells *see* autoimmune T cells
Self-nonself discrimination 235 (L), 247
antigen selected T-cell diversity 391
Self tolerance 12
intrathymic tolerization 573
molecular mechanisms underlying diabetes and other autoimmune diseases 49
post-thymic clonal deletion and anergy induction 574
suppressor T cells 523
T-cell receptors and homologous antigens 392
tumour immunity 536
Septic shock syndrome
reducing IL-1 activity 261
Serine/threonine kinases 223
see also signal transduction
Sex hormones 533
Signal transduction
apoptosis 586
FcR-mediation *see under* Fc
FK506 and cyclosporin as molecular probes 290
MHC class II *see* MHC class II
T-cell lymphokine expression 357
Skin
cutaneous immunology 75
cyclosporin A in the treatment of psoriasis 69
Langerhans cells *see* Langerhans cells
SLE *see* systemic lupus erythematosus
Soluble adhesion molecules 506 *see also* cell adhesion molecules
measurement 509
Soluble antigens
$CD8^+$ cytotoxic T cell responses 344
Somatic hypermutation *see* hypermutation
Sox-4 591
Spasmolysis 318
Steroids *see also* endocrine system
immunosuppression 323
Stromal microenvironments
intrathymic symbiosis 462
T-cell survival 529
Structure-based drug design (SBDD) 296
Superantigens 333
TCR–MHC interaction 208
Superoxide generation
FCγR mediation 217, 220
Suppressor T cells 523
Surrogate light (L) chain
Swine leucocyte antigens 147
Synovial T cells
reactive arthritis (ReA) 387
Synthetic peptides 474
Syphilis
vaccination strategies and DTH 576
Systemic lupus erythematosus (SLE) 323
targets of autoimmune attack 474

T
TAMs (tumour-associated macrophages) 142 (L)
TAP1/TAP2 333
T-cell independent (TI) antigens 15
T-cell receptors 333
antigen-selected diversity 391
CD3–TCR signalling 338, 539
immunosuppressive TCR antagonism 287
interactions with MHC 600
interaction with altered peptide ligands 602
interaction with MHC in superantigen activity 208
peptide recognition 597
TCRβ expression in early thymocyte development 460, 551, 610
TCR repertoire in autoimmune diseases 473
tolerance to self proteins 392
T cells
activation-induced cell death 338
inhibition by FK506 and cyclosporin 290
anergy in HIV infection 161
antagonism by altered peptide ligands 604
autoimmune *see* autoimmune T cells; immunosuppression
branching of alternative T-cell development pathways 550
$CD4^+$ *see* $CD4^+$ T cells
$CD8^+$ *see* $CD8^+$ cytotoxic T cells
control points during development 547
CR2 receptors 57
CsA, effects of 71
cytokine regulation 270, 523
differentiation 547 *see also* thymus
early development 547 *see also* thymus
early development 547, 591, 610
see also thymus
EBV/C3d receptors 56
extracellular matrix proteins in intrathymic migration and differentiation 158
functional uncoupling 179, 602
idiotypy 120
IL-2 receptor system 264
immunoglobulin class switching 15
immunological memory *see* memory T cells
immunosuppression *see* immunosupression
lifespan 235 (L)
maturation in the intestinal epithelium 140 (L)
maturation in the immune response 400
memory *see* memory T cells
MHC class II signalling *see* MHC class II
recognition of altered peptide ligands 602
responses to heat shock proteins 374
self–nonself discrimination 235 (L), 247
self tolerance 12, 473, 523, 573
signal transduction and lymphokine gene expression 357
skin immune system 77
suppressor cells 523
swine leucocyte antigens 147
TCR-α rearrangement and expression 552
TCRβ expression in early development 460, 551, 610
thymic microenvironment *see* thymus
transcription factors *see* transcription control
tumour-specific antigen recognition 483, 536 *see also* cancer vaccines
T-cell vaccination
proposed use in AIDS prevention 200, 615 (L)
Tcf-1 591
TCR *see* T-cell receptors
TCR–CD3 complex 177, 184, 338, 539, 597, 602, 610
functional uncoupling: the role of lck 179
transcription factors *see* transcription control
TGF-β (transforming growth factor β) 21
immunoglobulin class switching 15
T_H2 cytokines
maternal–fetal relationship 353
T_H cells 95 (L), 270
activation inhibited by FK506 and cyclosporin 290
adjuvants *see* adjuvants
antitumour response 311
IL-12 and generation of T_H1 cells 237 (L), 335
imbalance of T_H1 and T_H2 in HIV infection 107, 161, 304, 417 (L), 568 (L)
Thermotolerance 373
Thrombospondin 133
Thymic nurse cells (TNCs) 449
Thymic peptides 275, 276
Thymomimetic drugs 277
Thymus 137, 547
alternate T-cell development pathways 550
commitment to the T-cell lineage 547
cortical epithelium 446
cortical thymocyte-stromal cell symbiosis 464
destruction by HIV 304
developmental similarities between B cells and thymocytes 461
extracellular matrix (ECM) 450
extracellular matrix proteins in intrathymic T-cell migration and differentiation 158
induction of CD4 and CD8 expression 552
intrathymic selection and peripheral T-cell tolerance 473, 573
medullary epithelium 449

medullary thymocyte-stromal cell symbiosis 462
non-epithelial components 450
ontogeny 451
precursor cell differentiation 451
role of $p56^{lck}$ in thymocyte development 461, 551
structure and microenvironment 445
TCR-α rearrangement and expression 460, 549
TCR-β expression in early thymocyte development 460, 551, 610
TNF-α *see* tumour necrosis factor-α
Tolerance induction 287
cytokine-mediated suppression 523
immunosuppression by monoclonal antibodies 247
intrathymic 573
non-obese diabetic (NOD) mice 574
peripheral T-cell tolerance 473, 574
suppressor T cell 523
T-cell receptors and homologous antigens 392
tumour immunity 536
Transcriptional control
early T-cell development 591
lymphokine gene expression 359
Transforming growth factor beta *see* TGF-β
Transplantation immunology *see* grafts; organ transplantation
Treponema pallidum 576
antigenic components 579
Tuberculosis
T_H1/T_H2 switching and loss of $CD4^+$ T cells 568 (L)
Tuftsin 277
Tumour-associated macrophages *see* TAMS
Tumour cells 491
see also cancer
adoption of lymphocyte functions 398
CD44 and metastasis 101, 395
FcγR-mediated cytotoxicity 217, 220
HLA expression in benign and premalignant lesions 492
immunotherapy 245, 267
immunotoxins *see* immunotoxins
vaccines *see* cancer vaccines
Tumour necrosis factor-α (TNF-α)
AIDS therapy 304
antiviral role 155
maternal–fetal relationship 353
Tumour-specific antigens 483, 536
see also cancer vaccines
costimulation of T-cell responses 484
human melanoma 537
Two signal model (lymphocyte activation) 235 (L)
Tyrosine kinases 8, 222
MHC class II signalling 541
role of $p56^{lck}$ in thymocyte development 461, 551

U
Ubenimex 276
Urethritis 387

V
Vaccines
adjuvants *see* adjuvants
BCG vectors 580
cancer *see* cancer vaccines
cytotoxic T-cell responses induced by soluble antigens 344
enhancing role of FcγR 220
immunity at local sites of infection 334
recombinant vaccinia viruses (rVV) 155, 344, 579
syphilis 577
T-cell vaccination in AIDS prevention 200, 615 (L)
Vascular cell adhesion molecules (VCAM)-1 506, 509
Vasculitis 245, 500
VCAM-1 *see* vascular cell adhesion molecule-1 506, 509
Vesicular stomatitis virus 333
Veterinary immunology
swine leucocyte differentiation antigens 147
V genes
antibody hypermutation 405
autoreactive T cells 287
humanized antibodies 243
Viral immunology 333
Viral infection
antiviral role of cytokines 155
autoimmune disease 532
intra-epithelial virus neutralization by IgA 431
Viral superantigens *see* superantigens
Virus-related tumour growth 496
Vitronectin receptor integrin 132
$V_{pre\ B}$ genes 60
V-region
disease hypothesis (VRDH) 376, 380
encephalitogenicity 376
idiotypy 513
lymphocyte lifespans 38

X
Xenosensitization 422
Xenotransplantation 480
X-linked immunodeficiences
agammaglobulinaemia (XLA) 554
CD40 ligand 559
hyper-IgM syndrome (HIGM1) 560
X-ray crystallography
structure-based drug design (SBDD) 296

Z
Zalcitabine 303
Zeiosis 128
Zidovudine 303, 343
Zinc finger protein 593

Index of Books Reviewed

A
Aggarwal, B.B. and Gutterman, J.U., eds, *Human Cytokines: Handbook For Basic and Clinical Research* 47
Alt, F.W. and Vogel, H.J., eds, *Molecular Mechanisms of Immunological Self-Recognition* 419
Anderson, R.M. and May, R.M., *Infectious Diseases of Humans: Dynamics and Control* 616

B
Bartfai, T. and Ottoson, D., eds, *Neuroimmunology of Fever* 571

C
Celada, F. and Pernis, B., eds, *T Lymphocytes: Structure, Function, Choices* 420
Coffman, R.L., ed., *Regulation and Functional Significance of T-Cell Subsets* 570

D
Dealtry, G.B. and Rickwood, D., eds, *Cell Biology: Labfax* 371

F
Fleischer, B., ed., *Biological Significance of Superantigens* 191

G
Gupta, S., Paul, W.E., Cooper, M.D. and Rothenberg, E.V., eds, *Mechanisms of Lymphocyte Activation and Immune Regulation III: Developmental Biology of Lymphocytes* 471

L
Lewis, C.E. and McGee, J.O'D., eds, *The Natural Killer Cell* 96
Longobardi Givan, A., *Flow Cytometry: First Principles* 418

M
Medawar, J., *A Very Decided Preference – Life With Peter Medawar* 46
Mitchell, M.S., ed, *Biological Approaches to Cancer Treatment: Biomodulation* 516
Murphy, M.J., ed., *Concise Reviews in Clinical and Experimental Haematology* 239

N
National Research Council, ed., *Biologic Markers in Immunotoxicology* 240

O
Oliveira, D.B.G., *Immunological Aspects Of Renal Disease* 97

P
Patterson, R., ed., *Allergic Diseases: Diagnosis and Management* 472

R
Racz, P., Letvin, N.L. and Gluckman, J.C., eds, *Cytotoxic T Cells in HIV and Other Retroviral Infections* 238
Romagnani, S., ed., *New Advances on Cytokines* 470
Rose, N.R., Conway de Macario, E., Fahey, J.L., Friedman, H. and Penn, G.M., eds, *Manual Of Clinical Laboratory Immunology, 4th Edition* 145
Rothwell, N.J. and Dantzer, R.D., eds, *Interleukin-1 in the Brain* 471
Rouse, B.T., ed., *Herpes Simplex Virus – Pathogenesis, Immunobiology and Control* 144

S
Sexton, C., *The Seeds of Time – a Biography of MacFarlane Burnet* 46

W
Weiner, D.B., ed., *Acquired Immune Deficiency Syndrome* 517

Y
Yap, P.L., ed., *Clinical Applications of Intravenous Immunoglobulin Therapy* 48

Contents

Peer reviewed Viewpoint and Review articles from 1993

Dual antigen recognition by B cells
Carel J.M. van Noesel, Arjan C. Lankester and René A.W. van Lier 8

Multiple levels of peripheral tolerance
Bernd Arnold, Günther Schönrich and Günter J. Hämmerling 12

Towards a comprehensive view of immunoglobulin class switching
Clifford M. Snapper and James J. Mond 15

Colony stimulating factors, cytokines and monocyte–macrophages – some controversies
John A. Hamilton 18

Lymphocyte lifespans: homeostasis, selection and competition
António A. Freitas and Benedita B. Rocha 25

The dynamic relationship between B-cell populations in adults
Ian MacLennan and Eric Chan 29

The turnover of B-cell populations
Dennis G. Osmond 34

Lymphocyte survival and V-region repertoire selection
Antonio Coutinho 38

B-cell lifespans in the mouse – why to debate what?
Klaus Rajewsky 40

Mixed haplotypes and autoimmunity
Neal R. Nygard, Deborah M. McCarthy, Joel Schiffenbauer and Benjamin D. Schwartz 53

Expression of EBV/C3d receptors on T cells: biological significance
Constantine D. Tsoukas and John D. Lambris 56

The surrogate light chain in B-cell development
Fritz Melchers, Hajime Karasuyama, Dirk Haasner, Steven Bauer, Akira Kudo, Nobuo Sakaguchi, Bradford Jameson and Antonius Rolink 60

The mechanisms of action of cyclosporin A in the treatment of psoriasis
Robert L. Wong, Christine M. Winslow and Kevin D. Cooper 69

The skin immune system: progress in cutaneous biology
Jan D. Bos and Martien L. Kapsenberg 75

B-cell lineages exist in the mouse
Leonore A. Herzenberg and Aaron B. Kantor 79

B-1 cells are made, not born
Geoffrey Haughton, Larry W. Arnold, Alan C. Whitmore and Stephen H. Clarke 84

A Th1→ Th2 switch is a critical step in the etiology of HIV infection
Mario Clerici and Gene M. Shearer 107

Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes
Yoshiya Tanaka, David H. Adams and Stephen Shaw 111

Sequence homologies between hsp60 and autoantigens
David B. Jones, Andrew F.W. Coulson and Gordon W. Duff 115

What is an idiotype?
R. Jefferis 119

CD14: Cell surface receptor and differentiation marker
H.W.L. Ziegler-Heitbrock and R.J. Ulevitch 121

Apoptosis
J. John Cohen 126

Phagocyte recognition of cells undergoing apoptosis
John Savill, Valerie Fadok, Peter Henson and Chris Haslett 131

Do B cells drive the diversification of immune responses?
Mark J. Mamula and Charles A. Janeway, Jr 151

A case for cytokines as effector molecules in the resolution of virus infection
Alistair J. Ramsey, Janet Ruby and Ian A. Ramshaw 155

Extracellular matrix proteins in intrathymic T-cell migration and differentiation?
Wilson Savino, Dea Maria S. Villa-Verde and Joseli Lannes-Vieira 158

T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function?
Linde Meyaard, Hanneke Schuitemaker and Frank Miedema 161

Interleukin 1 receptors in the brain and endocrine tissues
Emmett T. Cunningham, Jr and Errol B. De Souza 171

Distinct roles for CD4 and CD8 as co-receptors in antigen receptor signalling
Michael Julius, Christiane R. Maroun and Loralee Haughn 177

The roles of CD8 in cytotoxic T lymphocyte function
Anne M. O'Rourke and Matthew F. Mescher 183

Can AIDS be prevented by T-cell vaccination?
Henri Atlan, Merril J. Gersten, Peter L. Salk and Jonas Salk 200

Determinant spreading and the dynamics of the autoimmune T-cell repertoire
Paul V. Lehmann, Eli E. Sercarz, Thomas Forsthuber, Colin M. Dayan and Guy Gammon 203

How do T-cell receptors, MHC molecules and superantigens get together?
David L. Woodland and Marcia A. Blackman 208

Growth hormone and prolactin are paracrine growth and differentiation factors in the haemopoietic system
Robert Hooghe, Mireille Delhase, Patricia Vergani, Anagha Malur and Elisabeth L. Hooghe-Peters 212

Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications
Jan G.J. van de Winkel and Peter J.A. Capel 215

Signal transduction by Fc receptors: the FcεR1 case
Michael A. Beaven and Henry Metzger 222

Lymphocyte Fc receptors: the special case of T cells
Matyas Sandor and Richard G. Lynch 227

Immunopharmacology: a joint issue with Trends in Pharmacological Sciences Humanized antibodies
Greg Winter and William J. Harris 243

The use of monoclonal antibodies to achieve immunological tolerance
Herman Waldmann and Stephen Cobbold 247

Immunotoxins: magic bullets or misguided missiles?
Ellen S. Vitetta, Philip E. Thorpe and Jonathan W. Uhr 252

Modalities for reducing interleukin 1 activity in disease
Charles A. Dinarello 260

The IL-2/IL-2 receptor system: a target for rational immune intervention
Thomas A. Waldmann 264

Cytokine regulation of T-cell function: potential for therapeutic intervention
Fiona Powrie and Robert L. Coffman 270

Immunostimulants
John W. Hadden 275

Adjuvants: current status, clinical perspectives and future prospects
Françoise M. Audibert and Luc D. Lise 281

Selective immunosuppression
Luciano Adorini, Jean-Charles Guéry, Gemma Rodriguez-Tarduchy and Sylvie Trembleau 285

FK506 and cyclosporin, molecular probes for studying intracellular signal transduction
Jun Liu 290

Structure-based drug design: applications in immunopharmacology and immunosuppression
Manuel A. Navia and Debra A. Peattie 296

Challenges in the therapy of HIV infection
Robert Yarchoan, Hiroaki Mitsuya and Samuel Broder 303

Cancer vaccines
Drew M. Pardoll 310

Immunopharmacology of asthma
John Morley 317

Immunosuppressive therapy of autoimmune diseases
Jean-François Bach 322

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation
Thomas E. Starzl, Anthony J. Demetris, Noriko Murase, Angus W. Thomson, Massimo Trucco and Camillo Ricordi 326

Antigen presentation, loss of immunological memory and AIDS
M.R. Helbert, J. L'age-Stehr and N.A. Mitchison 340

Can soluble antigens induce CD8+ cytotoxic T-cell responses? A paradox revisited
Syamal Raychaudhuri and W. John W. Morrow 344

Bidirectional cytokine interactions in the maternal–fetal relationship: is successful pregnancy a Th2 phenomenon?
Thomas G. Wegmann, Hui Lin, Larry Guilbert and Tim R. Mosmann 353

Signal transduction events leading to T-cell lymphokine gene expression
James D. Fraser, David Straus and Arthur Weiss 357

Myasthenia gravis: recognition of a human autoantigen at the molecular level
Maria Pia Protti, Angelo A. Manfredi, Robert M. Horton, Matteo Bellone and Bianca M. Conti-Tronconi 363

The V-region disease hypothesis: new evidence suggests it is probably wrong
Darcy B. Wilson, Lawrence Steinman and Daniel P. Gold 376

Reply by Ellen Heber-Katz and Hans Acha-Orbea 380

Epidermal Langerhans cells are critical for immunoregulation of cutaneous leishmaniasis
Heidrun Moll 383

Current perspectives in reactive arthritis
Gabrielle Kingsley and Jochen Sieper 387

Antigen-selected T-cell receptor diversity and self–nonself homology
Jean-Laurent Casanova and Janet L. Maryanski 391

CD44 splice variants: metastases meet lymphocytes
Peter Herrlich, Margot Zöller, Steven T. Pals and Helmut Ponta 395

The maturation of the immune response
Claudia Berek and Mike Ziegner 400

Discriminating intrinsic and antigen-selected mutational hotspots in immunoglobulin V-genes
Alexander G. Betz, Michael S. Neuberger and César Milstein 405

Cyclic re-entry of germinal center B cells and the efficiency of affinity maturation
Thomas B. Kepler and Alan S. Perelson 412

Defining criteria for autoimmune diseases (Witebsky's postulates revisited)
Noel R. Rose and Constantin Bona 426

A three-tiered view of the role of IgA in mucosal defense
Mary B. Mazanec, John G. Nedrud, Charlotte S. Kaetzel and Michael E. Lamm 430

HIV and human complement: mechanisms of interaction and biological implication
M.P. Dierich, C.F. Ebenbichler, P. Marschang, G. Füst, N.M. Thielens and G.J. Arlaud 435

An immunologist's look at the Rho and Rab GTP-binding proteins
Philippe Chavrier, Jean-Pierre Gorvel and Jacques Bertoglio 440

The thymic microenvironment
Richard L. Boyd, Carolyn L. Tucek, Dale I. Godfrey, David J. Izon, Trevor J. Wilson, Natalie J. Davidson, Andrew G.D. Bean, Heather M. Ladyman, Mary A. Ritter and Patrice Hugo 445

Is TCR β expression an essential event in early thymocyte development?
Donald B. Palmer, Adrian Hayday and Michael J. Owen 460

Development in the thymus: it takes two to tango
Mary A. Ritter and Richard L. Boyd 462

Interaction of the natural anti-gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans
Uri Galili 480

Costimulation of T cells for tumor immunity
Lieping Chen, Peter S. Linsley and Karl Erik Hellström 483

S-type mammalian lectins in allergic inflammation
Fu-Tong Liu 486

Natural history of HLA expression during tumour development
Federico Garrido, Teresa Cabrera, Angel Concha, Susan Glew, Francisco Ruiz-Cabello and Peter L. Stern 491

Role of heparan sulfate in immune system–blood vessel interactions
Nathan S. Ihrcke, Lucile E. Wrenshall, Bonnie J. Lindman and Jeffrey L. Platt 500

Circulating adhesion molecules in disease
Andrew J.H. Gearing and Walter Newman 506

A possible role for bcl-2 *in regulating T-cell memory – a 'balancing act' between cell death and survival*
Arne N. Akbar, Michael Salmon, John Savill and George Janossy 526

Retroviruses, apoptosis and autogenes
John D. Mountz and Norman Talal 532

Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells
Giorgio Parmiani 536

Structural compartmentalization of MHC class II signaling function
William F. Wade, Jean Davoust, Jean Salamero, Pascale André, Tania H. Watts and John C. Cambier 539

Control points in early T-cell development
Dale I. Godfrey and Albert Zlotnik 547

X-linked agammaglobulinemia – gene cloning and future prospects
Christine Kinnon, Steve Hinshelwood, Roland J. Levinsky and Ruth C. Lovering 554

CD40 ligand and its role in X-linked hyper-IgM syndrome
Robin E. Callard, Richard J. Armitage, William C. Fanslow and Melanie K. Spriggs 559

Delayed hypersensitivity, immune deviation, antigen processing and T-cell subset selection in syphilis pathogenesis and vaccine design
Stewart Sell and Pei-Ling Hsu 576

Programmed cell death, apoptosis and killer genes
Lawrence M. Schwartz and Barbara A. Osborne 582

Transcription factors in early T-cell development
Hans C. Clevers, Mariëtte A. Oosterwegel and Katia Georgopoulos 591

How αβ T-cell receptors 'see' peptide/MHC complexes
Yueh-hsiu Chien and Mark M. Davis 597

Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands
Brian D. Evavold, Joanne Sloan-Lancaster and Paul M. Allen 602

A role for a pre-T-cell receptor in T-cell development
Marcus Groettrup and Harald von Boehmer 610

Back Issues of Elsevier Trends Journals

Back issues from 1992 and 1993 are available to our customers at the following rates. Please state which issue(s) you require, including the volume and number (or year and month).

Issues(s): _____

_____

_____

Please tick how many issues you would like below. Issues are available in bulk at discounted rates – institutions/libraries must pay institutional rates.

Individual Rates

- ❑ Single issue £16.00/$25.00 each
- ❑ Five issues £68.00/$106.00 (includes 15% discount)
- ❑ Ten issues £120.00/$187.00 (includes 25% discount)

Institutional Rates

- ❑ Single issues £33.00/$52.00 each
- ❑ Five issues £140.00/$218.00 (includes 15% discount)
- ❑ Ten issues £248.00/$387.00 (includes 25% discount)

PAYMENT METHOD:

- ❑ Personal cheque, Eurocheque, or money order made payable to **Elsevier**
- ❑ Credit card
  - ❑ Visa/Barclaycard ❑ Mastercard/Access ❑ American Express

Card no: _____

Expiry date: _____

Name on card: _____ Signature: _____

Total Payment sent: _____

Name: _____

Position: _____

Address: _____

_____

_____

Zip/Post Code: _____

Country: _____

Telephone: _____ Fax: _____

Please send this order with payment to:

Marketing Department, Elsevier Trends Journals, 68 Hills Road, Cambridge UK CB2 1LA



genzyme

Leading to success in the cytokine research race requires a combination of scientific excellence and superior reagents. Genzyme can help accelerate your research by providing consistent quality, published applications, and guaranteed performance.

Genzyme offers the most complete line of mouse and human research products:

cytokines
growth factors
antibodies
receptor reagents
cell adhesion molecules
ELISA Kits

For research use only, not for use in diagnostic procedures.

For more information or to place an order, call 1-800-332-1042 (in USA) or contact your local Genzyme Sales Office:
Germany 49 6142/69 09 71 **Italy** 02/6127621 **UK** 800 373415
or your authorized Genzyme Distributor.

AR 27-3631 **AU** (02)5503222 **AT** (0222)4093961-0 **BE** 032523711 **BR** (011)881-3682
BG,RO 41-22-786-2236 **CA** (416)470-2520 **CL** 6989617 **CY** 2-383185 **DK** 2-948822 **EG** 23480997
FI 0-5281 **FR** (1) 30500050 **GR** 30-1 8836 757 **HU** 36-1-166-9995 **IS** 1-686044 **IN** (542)311473
IR 808 7602 **IL** 02-354276 **IT** (02)6127621 **JP** (03)3663-0723-0722 **KR** 02-924-8697 **KW** 2420496
MX 523-615-3385 **NL** 04132-51115 **NZ** (03) 5431255 **NO** 47-22-220411 **OM** (968) 794501
PK 2412601-3 **PL** 48-61-305-025 **PT** 858 15 64 **CH** 041-0614814713 **TW** (02)3683600 **TR** 1-2430022
AE 971-4-633591 **GB** (0)800 373 415 **YU, RU** 041-36 96 36

genzyme

ONE KENDALL SQUARE
CAMBRIDGE, MA 02139 USA
TEL: 617-252-7500
FAX: 617-252-7600

Copyright Genzyme Corporation 1993